Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | ATM | Q13315 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.53 |
| ▸ | GSK3B | P49841 | 2/20 | 0.52 |
| ▸ | MMP1 | P03956 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7925389 | 0.95 | KMT2A (0.59) | KMT2AMEN1CYP1A2ATML3MBTL1 | |
| SCHEMBL3841701 | 0.89 | HDAC1 (0.58) | KMT2AMEN1CYP1A2ATML3MBTL1 | |
| SCHEMBL7243792 | 0.89 | HDAC1 (0.63) | KMT2AMEN1CYP1A2ATML3MBTL1 | |
| SCHEMBL25169970 | 0.88 | HDAC1 (0.66) | KMT2AMEN1CYP1A2ATML3MBTL1 | |
| SCHEMBL20547390 | 0.86 | CYP4F2 (0.51) | KMT2AMEN1CYP1A2ATML3MBTL1 | |
| SCHEMBL11827259 | 0.85 | GSK3B (0.55) | KMT2AMEN1CYP1A2ATML3MBTL1 | |
| SCHEMBL241664 | 0.84 | GSK3B (0.70) | KMT2AMEN1ALDH1A1MAPTPOLB | |
| SCHEMBL417812 | 0.84 | KMT2A (0.62) | KMT2AMEN1CYP1A2ATML3MBTL1 | |
| SCHEMBL2305014 | 0.83 | HSD17B3 (0.60) | KMT2AMEN1CYP1A2ATML3MBTL1 | |
| SCHEMBL8535748 | 0.83 | KMT2A (0.63) | KMT2AMEN1ATMALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105039435-A | Method for producing (S)-bromobenzene methyl lactate through yeast | UNIV QINGDAO SCIENCE & TECHNOLOGY | 2015-11-11 | — | — | CN | claimed |
| US-20250382287-A1 | PHARMACEUTICALLY ACCEPTABLE SALT AND CRYSTAL FORM OF NITROGEN-CONTAINING BRIDGE HETEROCYCLIC DERIVATIVE, AND METHOD FOR PREPARING SAME | JIANGSU HENGRUI PHARMACEUTICALS CO LTD (CN) | 2025-12-18 | — | — | US | disclosed |
| US-20250250267-A1 | NITROGEN-CONTAINING BRIDGED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2025-08-07 | — | — | US | disclosed |
| EP-4549435-A1 | PHARMACEUTICALLY ACCEPTABLE SALT AND CRYSTAL FORM OF NITROGEN-CONTAINING BRIDGE HETEROCYCLIC DERIVATIVE, AND METHOD FOR PREPARING SAME | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2025-05-07 | — | — | EP | disclosed |
| EP-4545515-A1 | BCL-2 INHIBITORS | BeiGene Switzerland GmbH (CH) | 2025-04-30 | — | — | EP | disclosed |
| CN-119798256-A | Nitrogen-containing bridge heterocyclic compound, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2025-04-11 | — | — | CN | disclosed |
| CN-119798257-A | Nitrogen-containing bridge heterocyclic compound, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2025-04-11 | — | — | CN | disclosed |
| CN-119798258-A | Nitrogen-containing bridge heterocyclic compound, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2025-04-11 | — | — | CN | disclosed |
| EP-4522618-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS | Merck Patent GmbH (DE) | 2025-03-19 | — | — | EP | disclosed |
| CN-119403797-A | Pharmaceutically acceptable salt and crystal form of nitrogen-bridge heterocyclic derivative and preparation method thereof | 江苏恒瑞医药股份有限公司 | 2025-02-07 | — | — | CN | disclosed |
| US-6787671-B2 | FOR PRODUCTION OF ALDEHYDES, CARBOXYLIC ACIDS, ESTERS, OR KETONES VIA REACTION OF OSMIUM CATALYST AND PEROXYMONOSULFURIC ACID | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2004-09-07 | — | — | US | disclosed |
| EP-1432700-A1 | SPIRO-HYDANTOIN COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | Bristol-Myers Squibb Company (US) | 2004-06-30 | — | — | EP | disclosed |
| US-20040009998-A1 | Spiro-hydantoin compounds useful as anti-inflammatory agents | CEREP SA (FR) | 2004-01-15 | — | — | US | disclosed |
| CN-1462267-A | Process for preparing ketocarboxylic acid derivatives | BAYER ABTIENGESELLSCHAFT (DE) | 2003-12-17 | — | — | CN | disclosed |
| US-20030220517-A1 | Method for producing ketocarboxylic acid derivatives | BAYER CROPSCIENCE AG (DE) | 2003-11-27 | — | — | US | disclosed |
| US-20030149299-A1 | Catalytic osmium-assisted oxidative cleavage of olefins | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2003-08-07 | — | — | US | disclosed |
| WO-2003060852-A2 | CATALYTIC OSMIUM-ASSISTED OXIDATIVE CLEAVAGE OF OLEFINS | MICHIGAN STATE UNIVERSITY (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003029245-A1 | SPIRO-HYDANTOIN COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-04-10 | — | — | WO | disclosed |
| CN-1216522-A | Therapeutic agent for diabetes | JAPAN TOBACCO INC (JP) | 1999-05-12 | — | — | CN | disclosed |
| EP-0885869-A1 | THERAPEUTIC AGENT FOR DIABETES | Japan Tobacco Inc. (JP) | 1998-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250250267-A1 | NITROGEN-CONTAINING BRIDGED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | CFB, F11, CFH | KMT2A 4535/4885MEN1 100/4885CYP1A2 850/4885 |
| US-20030149299-A1 | Catalytic osmium-assisted oxidative cleavage of olefins | OXER1, OXSR1, AOX1 | KMT2A 3952/4885MEN1 4234/4885CYP1A2 361/4885 |
| US-20040009998-A1 | Spiro-hydantoin compounds useful as anti-inflammatory agents | ICAM1, VCAM1, SELL | KMT2A 1444/4885MEN1 4240/4885CYP1A2 474/4885 |
| US-20030220517-A1 | Method for producing ketocarboxylic acid derivatives | CYP2F1, HK1, FBP1 | KMT2A 2252/4885MEN1 469/4885CYP1A2 377/4885 |
| US-20250382287-A1 | PHARMACEUTICALLY ACCEPTABLE SALT AND CRYSTAL FORM OF NITROGEN-CONTAINING BRIDGE HETEROCYCLIC DERIVATIVE, AND METHOD FOR PREPARING SAME | SLC38A7, SLC28A1, ATIC | KMT2A 1329/4885MEN1 276/4885CYP1A2 1200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.